PMA supplement
N17600 S041: AVITENE (MICROFIBRILLAR COLLAGEN HOMOSTAT)
FDA PMA supplement · Real-Time Process · Davol Inc., Sub. C. R. Bard, Inc.
Key facts
| Original PMA | N17600 |
|---|---|
| Supplement number | S041 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | AVITENE (MICROFIBRILLAR COLLAGEN HOMOSTAT) |
| Generic name | Agent, absorbable hemostatic, collagen based |
| Applicant | Davol Inc., Sub. C. R. Bard, Inc. |
| Product code | LMF |
| Received date | Nov 12, 2024 |
| Decision date | Feb 18, 2025 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: